Global Glioblastoma Treatment Market – Industry Trends and Forecast to 2029

Get Exclusive Sample PDF of this Report Here

Glioblastoma Treatment Market Analysis and Size

The global glioblastoma treatment market is expected to witness significant growth during the forecast period. The growing prevalence of brain tumors is expected to increase the growth of the market during the forecast period. According to Global Cancer Observatory, in 2020, the prevalence of brain and CNS cancers was 308,102 worldwide and the number of deaths was 251,329 worldwide. Brain cancer is one of the toxic forms of cancer. The rising prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios are among the factors expected to boost the market growth. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global glioblastoma treatment market in the forecast period 2022-2029. The expected CAGR of global glioblastoma treatment market is tend to be around 9.30% in the forecast period of 2022 to 2029. The market was valued at USD 2.34 billion in 2021, and it would grow upto USD 4.77 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Glioblastoma is an aggressive form of malignant cancer that initiates from the star-shaped glial cells of the brain and spinal cord. Glioblastoma metastasis rapidly and is considered as most invasive form of glial tumors. Common symptoms include headache, nausea, vomiting, confusion, and decline in brain function. Numerous therapeutic options are available for the treatment of glioma. These include radiation therapy for glioma, chemotherapy, glioma targeted therapy, and surgery. Late stage clinical pipeline drugs can be highly effective treatment options for glioma. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Glioblastoma Treatment Market Scope and Segmentation

Get Exclusive Sample PDF of this Report Here

Global Glioblastoma Treatment Market Dynamics

Drivers

• Increase in Drug Approvals

The growing approval for novel therapy and combination therapy is estimated to boost the market in the upcoming years. For instance, in June 2019, the U.S. FDA permitted Pfizer’s Zirabev, which is a biosimilar for Avastin, used for the treatment of recurrent glioblastoma, NSCLC, and colorectal cancer, among others. In addition to this, in January 2020, the company launched its product in the U.S. Furthermore, in November 2019, the U.S. FDA accepted Samsung’s BLA application for its SB8 bevacizumab biosimilar candidate, which will boost the potential to launch products in the coming years. This boost the market growth.

• Rising Demand for Targeted Therapy

There has been a rising demand for the application of targeted therapy in glioblastoma patients. For instance, Bevacizumab is a targeted therapy that was approved for the treatment of recurrent and newly diagnosed glioblastoma. Additionally, in December 2017, the company received full approval from the U.S. FDA for bevacizumab for the treatment of glioblastoma in adults. The treatment is administered intravenously to stop the creation of new blood vessels that cut the blood supply and help to reduce the tumor. Continuation in clinical trials for the use of bevacizumab with other therapies is anticipated to boost the usage of the drug for the management of glioblastoma.

Opportunities

• Increased Cases of Glioma

According to the Case Reports in Oncology, 2018, approximately 200 cases were reported worldwide for glioblastoma multiforme. As a result, the market gains more attention and the growth is high due to the higher incidence of this diseased condition.

• Rising Healthcare Awareness

Health awareness amongst the population are rising, resulting in the prediction of drugs to boost market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching drugs that benefit the market.This creates more opportunities in the market.

• Growing Surgeries and Reimbursement Policies

The presence of reimbursement policies that boost healthcare professionals to maintain quality infrastructure is estimated to increase the demand for surgery in this market. Thus, more and more success rate of surgeries and reimbursement policies is surely expected to increase the market growth. In addition to this, increase in number of surgical procedures for the treatment of glioma in emergent economies, including China and India, is growing the segment. Governments of China and India have improved their healthcare spend, which in turn is augmenting the admission of patients in hospitals.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the treatment methods for this disease could curb the growth of the global glioblastoma treatment market over a forecast period.

• High Cost

The huge expenditure of the treatment methods surely hamper the market growth. Several treatments involved in this such as chemotherapy, targeted therapy, immunotherapy involve high cost which hampers the market growth.

This global glioblastoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global glioblastoma treatment market   contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Glioblastoma Treatment Market

COVID-19 has had a negative impact on the global glioma treatment market. Numerous ICU facilities, such as ventilators, personal protective equipment, and medical staff, were redirected to COVID-19 cases, stimulating the suspension of surgical neuro-oncology services during the COVID-19 pandemic. Instability in the facility of adequate medical care to critically-ill cancer patients was observed during the pandemic. Furthermore, glioblastoma patients are seem to be vulnerable to the COVID-19 infection, which resulted in the postponement of treatments and surgeries. Thus, the market was greatly impacted by the global glioma treatment market.

Global Glioblastoma Treatment Market Scope

The global glioblastoma treatment market   is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Primary
• Secondary

Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Glioblastoma Treatment Market Regional Analysis/Insights

The global glioblastoma treatment market   is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global glioblastoma treatment market   report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the rise cases of glioblastoma and favourable government policies as well as advanced healthcare facilities.

Asia-Pacific dominates the market due to the increase government initiatives and rapidly increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Glioblastoma Treatment Market Share Analysis

The global glioblastoma treatment market   overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global glioblastoma treatment market .

Key players operating in the global glioblastoma treatment market   include:

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)

SKU-54140